GlassScriptPhysician profile
Emily Cash
NPI 1669171641
$6,296.89
in general payments reported to CMS, 2019-2025
20 companies · $3,269 in 2025
The $3,269 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $2,856 · 2025: $3,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,225 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,225.40 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.76 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $863.39 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $627.53 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $621.96 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $482.26 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $419.25 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $400.13 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $328.96 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $293.74 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $274.72 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $214.99 | 2025 | Jornay Pm |
| Lundbeck LLC | $180.20 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Supernus Pharmaceuticals, INC. | $141.42 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $133.88 | 2024-2025 | Trintellix |
| Tris Pharma INC | $118.41 | 2024-2025 | Dyanavel Xr, Onyda Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.52 | 2024-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $53.54 | 2024-2025 | Quviviq, Quviviq |
| Biogen, INC. | $45.95 | 2024-2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $20.16 | 2024 | |
| Almatica Pharma LLC | $20.12 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Cash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.